Eli Lilly's obesity drug data impresses analysts — jump back into the weight-loss leader

Verdict: strong thesis, wrong side of the entry rules — wait

The verdict: wait, don't enter. The strongest point for the idea is fundamental momentum — Q2 2026 revenue of $23.0B rose 16.0% sequentially with gross margin expanding to 85.8%, and operating cash flow jumped 200% quarter over quarter to $16.0B. The strongest point against is the rule set itself: the exit condition (a daily close below the 50-day EMA at $1,172.31) is already met, RSI(14) at 32.36 needs a recovery of about 7.6 points, and the walk-forward testing produced fewer than two profitable folds — fold 3 lost 4.0% with a 9% win rate — so no robust parameter setup was established. Ownership filings for the period ended June 30, 2026 show net open-market insider selling of roughly $2.9 million across 20 holders (coverage state: deadline passed, not current), a sentiment flag rather than a trigger. The dividend record — a payout growing 15.3% annually to $6.00 per share in 2025, and $6.69 over the trailing twelve months — gives the thesis a floor while the stock regains its footing. What would flip the call: a daily close back above the 50-day EMA with RSI(14) above 40 and a tag of the 21-day EMA at $1,192.52.

Trade now

This is a wait, not an entry. The strategy wants LLY held long when price is above the 50-day EMA, the 21-day EMA is tagged, and RSI(14) is above 40. Right now only one piece is in place: the last close of $1,149.62 sits below the 21-day EMA at $1,192.52, so the pullback condition is effectively met. But price is about $22.69 below the 50-day EMA at $1,172.31, and RSI(14) reads 32.36 — roughly 7.6 points under the required level of 40. The exit rule is also currently in its trigger state (price below the 50-day EMA), so no position should be carried today. The historical evidence for this exact rule set over five years of daily bars is modest but real: an 8.4% total return across 39 trades, a 38.5% win rate, and a maximum drawdown of about 4.0%. The 12-month window alone returned roughly 3.0% with a 3.0% drawdown. Note that a bounded parameter search was run and no robust alternative setup was established — the configured rules stand as written. Concretely, waiting means: watch for a daily close back above $1,172.31 (the 50-day EMA), RSI(14) recovering above 40, and a session in which the low touches or pierces $1,192.52 while the close holds at or above it. Until all of those line up, there is no trade. If an entry does trigger, the built-in risk controls are a hard stop at -6% from entry and a 10% take-profit; sizing is capped at 2% account risk per trade and a 20% maximum position. Skip any discretionary entry that arrives while price is below the 50-day EMA — that is precisely the condition the strategy treats as an exit.

The fundamentals are doing the heavy lifting behind the obesity narrative

The thesis here is straightforward: Eli Lilly's obesity franchise is durable, and the data presentation at the major medical conference (per the Bloomberg piece on June 8, 2026) reinforced that the pipeline isn't a single-product story. The fundamentals back that read. Full-year 2025 revenue came in at $65.2B, up 44.7% year over year, with a gross margin of 83.0% — and the momentum carried into 2026: Q2 revenue of $23.0B rose 16% sequentially from Q1's $19.8B, and gross margin expanded further…

Scores

• Conviction score breakdown: 53
• Thesis support: 75
• Trade readiness: 25
• Risk quality: 50
• Backtest evidence: 45
• Fundamentals trend: 70

Watch items

• LLY — RSI (14)
• LLY — Daily close vs 50-day EMA
• LLY — Low vs 21-day EMA
• LLY — Price vs nearest support
• LLY — Dividend ex-date
• LLY — Price above EMA (50)
• LLY — Price
• LLY — RSI (14) above 40
• LLY — Price below EMA (50)